ScopeSys
Business Services · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
CanadaWebsite
www.scopesys.caRevenue
<$5 MillionIndustry
About ScopeSys
ScopeSys is a commercial-stage developer specializing in disruptive technologies for single-molecule imaging, particularly in genomic-medicine drug development. Their patented Convex Lens-induced Confinement (CLiC) technology enables high-throughput measurements with single-molecule resolution, allowing for novel analysis capabilities in the development of RNA, DNA, and nanoparticle delivered drugs. By resolving single-molecule interactions, ScopeSys enhances the engineering of active pharmaceutical ingredients and formulations, optimizing therapeutic sequences and mRNA loading. The company aims to collaborate with industry leaders to address real-world challenges in drug development.Explore more
ScopeSys Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to ScopeSys
Compare insights from companies similar to ScopeSys, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ScopeSys Tech Stack
A closer look at the technologies used by ScopeSys
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ScopeSys
Sign Up For FreeTo access detailed company insights
ScopeSys is a commercial-stage developer specializing in disruptive technologies for single-molecule imaging, particularly in genomic-medicine drug development. Their patented Convex Lens-induced Confinement (CLiC) technology enables high-throughput measurements with single-molecule resolution, allowing for novel analysis capabilities in the develo... Read More
